桑杞颗粒对I-II级高血压血压及内皮功能障碍影响的随机双盲双模拟对照试验研究方案
本研究为随机双盲双模拟对照试验,计划纳入300例I或II级高血压患者,按1:1:1随机分为桑杞颗粒组、氯沙坦组及联合组,主要终点为各组药物有效率,次要终点包括昼夜血压变化、靶器官损害及血管内皮功能指标,旨在评估桑杞颗粒的疗效与安全性并探索其降压机制。
要点
- 桑杞颗粒可能通过保护血管内皮功能发挥降压作用,尚需临床试验证实。
- 试验采用双盲双模拟设计,三组分别接受桑杞颗粒、氯沙坦或两者联合治疗。
- 主要终点为药物有效率,次要终点涵盖血压变异性、靶器官损害及血清内皮指标。
核心结论
- 本研究旨在为桑杞颗粒治疗高血压的疗效和安全性提供临床证据,并探索其可能的作用机制。
研究设计与样本
- 随机双盲双模拟对照试验,计划纳入300例I或II级高血压患者,按1:1:1随机分为三组。
- A组接受桑杞颗粒联合氯沙坦安慰剂,B组接受氯沙坦联合桑杞颗粒安慰剂,C组接受桑杞颗粒联合氯沙坦。
- 桑杞颗粒10g每日两次,氯沙坦50mg每日晨服一次。
关键数值与推荐
- 主要终点为各组药物有效率。
- 次要终点包括日间和夜间平均收缩压及舒张压变化、夜间血压下降率变化。
- 靶器官损害评估包括心率变异性、踝臂血压指数和脉搏波传导速度。
- 症状改善评估采用高血压症状量表、中医证候积分量表、匹兹堡睡眠质量指数、焦虑自评量表、抑郁自评量表和36项短表健康调查。
- 血清血管功能指标包括ET-1、TXA2、NO和PGI2水平变化。
临床怎么用
- 若证实有效,桑杞颗粒可能为I或II级高血压患者提供一种兼顾内皮功能保护的治疗选择。
局限性
- 原文未报告研究结果,无法评估疗效和安全性。
- 试验仅纳入I或II级高血压患者,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Worldwide, hypertension is an important public health challenge because of its high prevalence and the concomitant risks of cardiovascular disease. It induces half of the coronary heart disease and approximately two-thirds of the cerebrovascular disease burden. Vascular endothelial dysfunction has important roles in the pathophysiology of essential hypertension. Types I and II hypertension can be treated with sang-qi granules (SQG), a Chinese herbal formula. Several experimental studies on animals have shown that SQG can lower blood pressure and myocardial fibrosis by suppressing inflammatory responses. However, no standard clinical trial has confirmed this. Whether SQG can improve endothelial cell function is unknown. METHODS/DESIGN: In this randomized double-blind double-simulation controlled trial, 300 patients with stage I or II hypertension will be recruited and randomly allocated in a 1:1:1 ratio to group A (treatment with SQG and placebo instead of Losartan), group B (treatment with Losartan and placebo instead of SQG), and group C (treatment with SQG and Losartan). In this study, 10 g of SQG (or its placebo) will be administrated twice a day and 50 mg of Losartan (or its placebo) will be administrated once in the morning. The primary endpoint is the drug efficiency for each of the three groups. The secondary endpoints are the change in average systolic and diastolic blood pressure during the day and the night, the change in the rate at which blood pressure drops at night, assessment of target organ damage (heart rate variability, ankle-brachial pressure index, and pulse wave velocity), assessment of any improvement in symptoms (Hypertension Symptom Scale, syndrome integral scale in traditional Chinese medicine, Pittsburgh Sleep Quality Index Scale, Self-Rating Anxiety Scale, Self-Rating Depression Scale, and the 36-Item Short Form Health Survey), blood lipids, serum indicators of vascular function (changes in serum levels of ET-1, TXA2, NO, and PGI2), and safety indicators. DISCUSSION: This study aims to provide clinical evidence on the efficacy and safety of SQG in the treatment of hypertension. Moreover, the possible mechanism by which SQG may lower blood pressure will be explored by observing the protective effect of SQG on vascular endothelial function, as well as its effect on related clinical symptoms, risk factors, and the target organs of hypertension. TRIAL REGISTRATION: Chinese Clinical Trials Registry, ChiCTR1800016427. Registered on 1 June 2018.
引用
- Shi H, Yang D, Qiao J, et al. Effects of sang-qi granules on blood pressure and endothelial dysfunction in stage I or II hypertension: study protocol for a randomized double-blind double-simulation controlled trial. Trials. 2020. PMID: 31907056. doi:10.1186/s13063-019-3690-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。